Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.

Bhaduri G, Roy S, Kalia A, Gokalani R, Saboo B

Clinical obesity1 Oct 2026

PMID42584177PMCIDPMC13464048DOI10.1111/cob.70105PepBankPUB-42584177

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewSafety outcome
In patients receiving semaglutide, the pooled risk ratio for depression versus comparators was 1.25, not statistically significant.
In plain wordsIn pooled studies, depression was not significantly more common in people taking semaglutide than in comparison groups.
Peptide
Semaglutide
Outcome
No significant changeDepression risk
Study
n: not reported in source
Comparator
Comparator or placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Measurements
Pooled risk ratio
1.25
depression
Source sentences
Summary
The pooled risk ratio for depression was 1.25 (95% CI: 0.95-1.65; I² = 98%).
1 context sentence(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis evaluated depression risk among patients receiving semaglutide.
Report a problemFND-4258417701
02HumanSystematic reviewSafety outcome
In patients receiving semaglutide, the pooled risk ratio for anxiety versus comparators was 1.22, not statistically significant.
In plain wordsIn pooled studies, anxiety was not significantly more common in people taking semaglutide than in comparison groups.
Peptide
Semaglutide
Outcome
No significant changeAnxiety risk
Study
n: not reported in source
Comparator
Comparator or placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Measurements
Pooled risk ratio
1.22
anxiety
Source sentences
Summary
For anxiety and suicidal ideation/attempt, pooled risk ratios were 1.22 (95% CI: 0.93-1.60; I² = 99%)
1 context sentence(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis evaluated depression risk among patients receiving semaglutide.
Report a problemFND-4258417702
03HumanSystematic reviewSafety outcome
In patients receiving semaglutide, the pooled risk ratio for suicidal ideation or attempt versus comparators was 1.20, not statistically significant.
In plain wordsIn pooled studies, suicidal thoughts or attempts were not significantly more common in people taking semaglutide than in comparison groups.
Peptide
Semaglutide
Outcome
No significant changeSuicidal ideation or attempt risk
Study
n: not reported in source
Comparator
Comparator or placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Measurements
Pooled risk ratio
1.2
suicidal ideation/attempt
Source sentences
Summary
1.20 (95% CI: 0.90-1.62; I² = 92%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Pooled estimates did not show a statistically significant increase in depression, anxiety or suicidal ideation/attempt among patients receiving semaglutide compared with comparator groups.
Summary · context
This systematic review and meta-analysis evaluated depression risk among patients receiving semaglutide.
Report a problemFND-4258417703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.